{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:36:41Z","timestamp":1791193001949,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T00:00:00Z","timestamp":1283990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Unresectable colorectal liver metastases have a 1\u2010 and 2\u2010year survival of 55% and 33% with current systemic therapies. The authors evaluated response and survival after transarterial chemoembolization.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Chemoembolization with cisplatin, doxorubicin, mitomycin C, ethiodized oil, and polyvinyl alcohol particles was performed at monthly intervals for 1 to 4 sessions. Cross\u2010sectional imaging and clinical and laboratory evaluation were performed before treatment, 1 month after treatment, and then every 3 months. A second cycle was performed for intrahepatic recurrence. Toxicity was assessed using National Cancer Institute's Common Toxicity Criteria version 3.0. Response was evaluated using Response Evaluation Criteria in Solid Tumors criteria. Progression and survival were estimated with Kaplan\u2010Meier analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>A total of 245 treatments were performed over 141 cycles on 121 patients. Ninety\u2010five of 141 treatment cycles were evaluable for response: 2 (2%) partial response, 39 (41%) stable disease, and 54 (57%) progression. Median time to disease progression (TTP) in the treated liver was 5 months, and median TTP anywhere was 3 months. Median survival was 33 months from diagnosis of the primary colon cancer, 27 months from development of liver metastases, and 9 months from chemoembolization. Survival was significantly better when chemoembolization was performed after first\u2010 or second\u2010line systemic therapy (11\u201012 months) than after third\u2010 to fifth\u2010line therapies (6 months) (<jats:italic>P<\/jats:italic> = .03). Presence of extrahepatic metastases did not adversely affect survival (<jats:italic>P<\/jats:italic> = .48).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Chemoembolization provided local disease control of hepatic metastases after 43% of treatment cycles. Median survival was 27 months overall, and 11 months when initiated for salvage after failure of second\u2010line systemic therapy. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25387","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T15:39:31Z","timestamp":1284046771000},"page":"343-352","source":"Crossref","is-referenced-by-count":110,"title":["Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol"],"prefix":"10.1002","volume":"117","author":[{"given":"Marissa","family":"Albert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew V.","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Fraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Tuite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. William","family":"Stavropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Mondschein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Soulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511722226.020"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-006-0372-5"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1250::AID-CNCR7>3.0.CO;2-J"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.113"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431302"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.066"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9930"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02055430"},{"key":"e_1_2_6_13_2","first-page":"95","article-title":"Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5\u2010fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Pugent Sound Oncology Consortium","volume":"5","author":"Bavisotto LM","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1074718"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therase P","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199909000-00004"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1997.01430290051008"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5278"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.189.2.8210369"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2501080295"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.tvir.2007.08.008"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","unstructured":"HarmantasA RotsteinLE LangerB.Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: is there a survival difference? Meta\u2010analysis of the published literature. Cancer.1996;78:1639\u20101645.","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1639::AID-CNCR1>3.0.CO;2-9"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940915)74:6<1706::AID-CNCR2820740611>3.0.CO;2-J"},{"issue":"16","key":"e_1_2_6_24_2","first-page":"413","article-title":"A pilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization","volume":"23","author":"Britten CD","year":"2005","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_25_2","unstructured":"BrittenC.A phase II study of rhuMAb VEGF (BEVACIZUMAB) in patients with hepatocellular carcinoma receiving chemoembolization.ClinicalTrials.govIdentifier: NCT00049322. Los Angeles CA: Jonsson Comprehensive Cancer Center National Cancer Institute;2010."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2472062029"},{"key":"e_1_2_6_27_2","first-page":"1085","article-title":"Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan\u2010eluting beads: results of a phase II clinical study","volume":"21","author":"Fiorentini G","year":"2007","journal-title":"In Vivo."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/539795"},{"key":"e_1_2_6_29_2","first-page":"2077","article-title":"TACE of liver metastases from colorectal cancer adopting irinotecan\u2010eluting beads: beneficial effect of palliative intra\u2010arterial lidocaine and postprocedure supportive therapy on the control of side effects","volume":"55","author":"Fiorentini G","year":"2008","journal-title":"Hepatogastroenterology."},{"key":"e_1_2_6_30_2","first-page":"77","article-title":"Chemoembolization of hepatic malignancies","volume":"8","author":"Soulen MC.","year":"1994","journal-title":"Oncology (Williston Park)"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25387","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:57:20Z","timestamp":1760259440000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,9]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1,15]]}},"alternative-id":["10.1002\/cncr.25387"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25387","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,9]]}}}